CytomX Therapeutics Inc (NASDAQ:CTMX) price on current trading day, rose 10.93% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.67.
A look at the stock’s price movement, the close in the last trading session was $0.60, moving within a range at $0.6005 and $0.67. The beta value (5-Year monthly) was 1.043 while the PE ratio in trailing twelve months stood at 1.70. Turning to its 52-week performance, $5.85 and $0.56 were the 52-week high and 52-week low respectively. Overall, CTMX moved -15.78% over the past month.
CytomX Therapeutics Inc’s market cap currently stands at around $53.65 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-05.
Analysts have a consensus estimate of 28.52M for the company’s revenue for the quarter, with a low and high estimate of 12.5M and 38.5M respectively. The average forecast suggests down to a -31.21% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 101.2M, representing a -26.72% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CTMX is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 3 recommend CTMX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CTMX’s current price about 0.69% and -14.67% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.26, while 7-day volatility ratio is 9.57% and 9.04% in the 30-day chart. Further, CytomX Therapeutics Inc (CTMX) has a beta value of 1.36, and an average true range (ATR) of 0.06. Analysts have given the company’s stock an average 52-week price target of $3.465, forecast between a low of $3.25 and high of $3.68. Looking at the price targets, the low is -385.07% off current price level while to achieve the yearly target high, price needs to move -449.25%. Nonetheless, investors will most likely welcome a -417.16% jump to $3.465 which is the analysts’ median price.
If we refocus on CytomX Therapeutics Inc (NASDAQ:CTMX), historical trading data shows that trading volumes averaged 6.76 over the past 10 days and 1.87 million over the past 3 months. The company’s latest data on shares outstanding shows there are 80.10 million shares.
The 2.56% of CytomX Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 58.41% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.7 million on 2025-02-28, giving us a short ratio of 6.67. The data shows that as of 2025-02-28 short interest in CytomX Therapeutics Inc (CTMX) stood at 590.0 of shares outstanding, with shares short rising to 4.55 million registered in 2025-01-31. Current price change has pushed the stock -34.98% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CTMX stock continues to rise going into the next quarter.
